This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BioDelivery (BDSI) Q3 Earnings Beat, Sales In Line, Stock Up
by Zacks Equity Research
BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q3. Sales were almost in line with the consensus mark.
Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat
by Zacks Equity Research
Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.
Endo International (ENDP) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Endo (ENDP) delivered earnings and revenue surprises of 20.34% and 6.96%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
What's in the Cards for BioSpecifics (BSTC) in Q3 Earnings?
by Zacks Equity Research
On BioSpecifics' (BSTC) Q3 conference call, investor focus will be on its progress with the development of CCH for treating uterine fibroids.
Endo (ENDP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are expected to focus on the Xiaflex performance and pipeline updates when Endo (ENDP) reports third-quarter results.
Analysts Estimate Endo International (ENDP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Endo (ENDP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug
by Zacks Equity Research
The EMA validates Rigel Pharmaceuticals' (RIGL) marketing application for thrombocytopenia drug, Tavalisse.
Best ETFs & Stocks From the Top Sector of Q3
by Sweta Killa
Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.
Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error
by Zacks Equity Research
Endo International (ENDP) recalls two lots of Robaxin 750mg Tablets due to wrong dosing information on the label.
Forget Mylan, Invest in These 3 Generic/Drug Stocks Instead
by Ekta Bagri
Given the recent spate of setbacks suffered by Mylan (MYL), we suggest investing in better-ranked generic/drug companies with favorable growth profile.
Has Endo International plc (ENDP) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ENDP) Outperforming Other Medical Stocks This Year?
Is Endo International (ENDP) a Great Stock for Value Investors?
by Zacks Equity Research
Is Endo International (ENDP) a great pick from the value investor's perspective right now? Read on to know more.
The Zacks Analyst Blog Highlights: Ingersoll-Rand, Endo International, Glanbia and Smurfit Kappa Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Ingersoll-Rand, Endo International, Glanbia and Smurfit Kappa Group
Irish Economy Rebounds in Q2: 4 Great Picks
by Nitish Marwah
Ireland's growth in the past few years not only shows its resilience to the economic downturn in the EU but also makes it one of the most business-friendly destinations of the region.
Endo (ENDP) Up 4.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Endo (ENDP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen Begins Phase III Study on Ischemic Stroke Candidate
by Zacks Equity Research
Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.
Endo (ENDP) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Endo (ENDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol
by Zacks Equity Research
Esperion Therapeutics' (ESPR) combination regimen of bempedoic acid and Merck's Zetia achieves significant reduction in bad cholesterol in a phase III study.
Ionis Pharmaceuticals (IONS) Looks Good: Stock Adds 7.8% in Session
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Jazz's (JAZZ) Leukemia Drug Vyxeos Gets Approval in Europe
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
Lannett Set to Lose Distribution Agreement With Key Supplier
by Zacks Equity Research
Lannett Company's (LCI) distribution agreement with key supplier, Jerome Stevens Pharmaceuticals, not to be renewed on expiry. Shares plunge.
Zacks.com highlights: Medifast, Endo International, HCA Healthcare, Five9 and FTI Consulting
by Zacks Equity Research
Zacks.com highlights: Medifast, Endo International, HCA Healthcare, Five9 and FTI Consulting
Buy These 5 Low-Beta Stocks to Brave Market Volatility
by Zacks Equity Research
In this article, we have come up with an investment strategy that clearly shows that less risky securities can also generate handsome returns if some parameters are considered.